References

  1. George ED, Sadovsky R. Multiple myeloma: recognition and management. Am Fam Physician. 1999;59(7):1885-1894.
  2. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology. 2004;231(1):11-23.
  3. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007. http://seer.cancer.gov/csr/1975_2004/. Accessed November 12, 2007.
  4. Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years: report of 10 cases and review of the literature. Arch Intern Med. 1996;156(13):1463-1468.
  5. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57(5):301-318.
  6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
  7. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63(5):912-916.
  8. Csire M, Mikala G, Peto M, et al. Detection of four lymphotropic herpesviruses in Hungarian patients with multiple myeloma and lymphoma. FEMS Immunol Med Microbiol. 2007;49(1):62-67.
  9. Bakkus MH, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol. 1994;87(1):68-74.
  10. Raje N, Anderson KC. Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. Blood. 2000;96(2):381-383.
  11. Bengtsson AK, Ryan EJ. Immune function of the decoy receptor osteoprotegerin. Crit Rev Immunol. 2002;22(3):201-215.
  12. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet. 2000;355(9200):248-250.
  13. Multiple Myeloma Research Foundation. Classification and staging. http://www.multiplemyeloma.org/about_my eloma/2.06.php. Accessed October 7, 2007.
  14. Kyle RA. Current therapy of multiple myeloma. Intern Med. 2002;41(3):175-180.
  15. Ludwig H. Advances in biology and treatment of multiple myeloma. Ann Oncol. 2005;16 (suppl 2):ii106-ii112.
  16. Lust JA, Donovan KA. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control. 1998;5(3):209-217.
  17. Multiple Myeloma Research Foundation. Bisphosphonates overview. http://www.multiplemyeloma.org/treatments/3.06.php. Accessed October 7, 2007.
  18. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719-3736.
  19. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
  20. Khosla S, Burr D, Cauley J, et al; American Society for Bone. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22:1479-1491.

 
 
 
 

  • 500 reads
 0